Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649904 · ClinicalTrials.gov registry record · NA
AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis
A NA study of Subarachnoid Hemorrhage and Intraventricular Hemorrhage, sponsored by Ohio State University.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT05649904: Recruiting NA study of Subarachnoid Hemorrhage and Intraventricular Hemorrhage, sponsored by Ohio State University.
NCT05649904 is a NA study of Subarachnoid Hemorrhage and Intraventricular Hemorrhage that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 240 participants, below the 3,576-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05649904, a NA study of Subarachnoid Hemorrhage and Intraventricular Hemorrhage, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD). Subjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.
Conditions Studied
Interventions
- DEVICE IRRAflow with Active Fluid Exchange System
- DEVICE External Ventricular Drain
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2026-01 |
| Phase | NA |
What NCT05649904 shows while recruiting
NCT05649904 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 3,576-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which IRRAflow with Active Fluid Exchange System is the first listed.
NCT05649904 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05649904 about?
NCT05649904 is a clinical study titled "AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis". The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (...
What is the current status of trial NCT05649904?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2023-02-07. Estimated completion is 2026-01.
What conditions does trial NCT05649904 study?
This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Intraventricular Hemorrhage, Ventriculitis, Subdural Hematoma.
What interventions are being tested in trial NCT05649904?
The interventions under investigation include: IRRAflow with Active Fluid Exchange System (DEVICE), External Ventricular Drain (DEVICE).
Who is sponsoring clinical trial NCT05649904?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05649904 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05649904's enrollment target sits among peer trials
240 7th of 21 higher than 15 of 21 other Subarachnoid Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Subarachnoid Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Auricular VNS Following Subarachnoid Hemorrhage
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
-
Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage
RECRUITING · NA
-
Cerebral Perfusion Pressure (CPP) Management Information Feedback and Nursing
COMPLETED · NA
-
Early Intensive Physical Therapy in Subarachnoid Hemorrhage
COMPLETED · NA
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI